Brief: Nabriva Therapeutics And Sinovant Sciences Restructure License Agreement For Xenleta For Community-Acquired Bacterial Pneumonia In China
07/12/2020 12:27
Dec 7 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA THERAPEUTICS AND SINOVANT SCIENCES RESTRUCTURE
LICENSE
AGREEMENT FOR XENLETA FOR COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA
IN CHINA
* NABRIVA THERAPEUTICS PLC - ACCELERATES MILESTONE PAYMENTS
TO
NABRIVA, INCLUDING Q4 2020 PAYMENT OF $1 MILLION
* NABRIVA THERAPEUTICS - RESTRUCTURED AGREEMENT PROVIDES
ADDITIONAL MANUFACTURING COLLABORATION TO EXPEDITE XENLETA
DELIVERY TO GREATER CHINA PATIENTS
* NABRIVA THERAPEUTICS PLC - RESTRUCTURED AGREEMENT
ACCELERATES
COMPONENTS OF $5 MILLION MILESTONE PAYMENT TO NABRIVA
Source text for Eikon: ID:nGNX1lXXSn
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update